The Anti-Aging Supplement Hype: What Actually Works?

← Back to articles

The longevity supplement market has exploded into a multi-billion dollar industry, fueled by compelling preclinical data, high-profile scientific advocates, and the deep human desire to slow biological aging. NMN, resveratrol, and spermidine now fill pharmacy shelves alongside more established vitamins, each promising to extend healthspan, reverse biological age, or activate ancient cellular repair pathways. The marketing is sophisticated, the science sounds credible, and the prices are high.

A sober assessment of the human clinical trial data reveals a consistent pattern: the mouse results that launched these supplements were genuinely exciting; the translation to humans has been, so far, disappointing.

NMN and NAD+ Precursors: Biomarker Changes Without Benefits

Nicotinamide mononucleotide (NMN) and its close relative nicotinamide riboside (NR) raise blood NAD+ levels reliably and consistently in human trials — this part is not in dispute. What is disputed is whether this biomarker change translates into any measurable health benefit. As of early 2026, over a dozen published RCTs have tested these compounds in humans. The findings have been uniformly underwhelming for clinical outcomes: no significant improvements in insulin sensitivity (the primary endpoint in a major Washington University trial), no cognitive improvements in healthy adults, no consistent changes in muscle function, body composition, or inflammatory markers.

One small Japanese trial (n=42) found improvements in walking speed in men over 65, and this remains the most frequently cited positive finding. It has not been replicated. The honest evidence-based position is: NMN raises a biomarker whose health significance is unproven, at a cost of $60–120/month, with no demonstrated clinical benefit in healthy humans at marketed doses.

Resveratrol: The Sirtuin Story Unraveled

Resveratrol burst into public consciousness in the mid-2000s when David Sinclair's lab at Harvard reported it activated sirtuins (longevity-associated proteins) and extended lifespan in yeast, worms, and flies. In obese mice, high-dose resveratrol improved metabolic markers and extended lifespan. The media coverage was extraordinary. Supplements appeared almost immediately.

The subsequent decade of human research has been systematically deflating. GlaxoSmithKline acquired Sirtris Pharmaceuticals (a resveratrol-focused company co-founded by Sinclair) for $720 million in 2008, then shut it down in 2013 after clinical trials failed to show benefit. Multiple human trials have found no significant effects on lifespan markers, cardiovascular risk factors, insulin sensitivity, or inflammation in healthy adults. A landmark 2014 study in JAMA Internal Medicine found that resveratrol intake (measured by urinary metabolites) in an elderly Italian cohort was not associated with longer lifespan, less cancer, less cardiovascular disease, or less inflammation — if anything, higher resveratrol was associated with slightly worse outcomes.

The bioavailability problem is severe: resveratrol is rapidly metabolized in the gut and liver, with less than 1% of an oral dose reaching systemic circulation in its active form. The doses used in positive mouse studies, when scaled to human body weight, would be unrealistically large. Modified forms (micronized, liposomal) improve bioavailability modestly but have not produced compelling clinical results.

Spermidine: Autophagy Activation With Limited Human Data

Spermidine is a polyamine found naturally in wheat germ, soybeans, aged cheese, and mushrooms. Its proposed longevity mechanism — autophagy induction (the cellular "self-cleaning" process that degrades damaged proteins and organelles) — is mechanistically sound and supported by strong preclinical data. In animal models, spermidine supplementation has extended lifespan across multiple species and improved cardiovascular and cognitive function.

In humans, the story is far shorter. A small proof-of-concept trial by Wirth et al. (Cortex 2018, PMID 29427839) found modest memory improvements with spermidine in older adults with subjective cognitive decline; the larger SmartAge follow-up by Schwarz et al. (Lancet Healthy Longevity 2022, PMID 34756517) using 0.9 mg/day of a wheat-germ extract for 12 months in 100 participants did not find significant improvement in the primary memory endpoint versus placebo. The wheat germ-based products used in these trials provide spermidine at levels achievable through dietary means for someone eating a varied plant-rich diet. Whether isolated supplementation beyond dietary levels provides meaningful additional benefit in healthy adults remains unproven.

What the Evidence Actually Supports for Longevity

The contrast between the hype around these three compounds and the evidence for other interventions is stark. Regular aerobic exercise is the most consistently and robustly documented intervention for extending healthspan in humans — it activates AMPK, reduces mTOR activity, induces autophagy, raises NAD+ through NAMPT activation, and has cardiovascular, metabolic, and cognitive benefits in hundreds of large RCTs. Caloric restriction and time-restricted eating have human trial data supporting improvements in multiple aging-associated biomarkers. Smoking cessation remains the single highest-impact modifiable longevity intervention available to smokers.

None of these require a monthly subscription. The supplement industry has been extraordinarily effective at monetizing the aspiration for convenient biological shortcuts in a space where the science is genuinely preliminary and the consumer verification burden is essentially zero. Watch the spermidine and NMN spaces — larger trials are ongoing and results could shift the picture. But as of now, paying premium prices for these compounds means paying for potential, not proven benefit.